a b c d e f g h i j k l m n o p q r s t u v w x y z #

Consumer Medication Information Leaflets / Risalah Maklumat Ubat untuk Pengguna (RiMUP)

 Search by Brand Name or Active Ingredients



  1. Consumer Medication Information Leaflet (RiMUP) is a copy of patient information leaflet for a medicine, which outline the conditions under which the medicine should be used and information on its known safety.
  2. Product registration holders are responsible for producing RiMUP, using a format template set by NPRA. The information in RiMUP must be in-line with the approved package insert at the time the RiMUP was evaluated by NPRA by using layman words.
  3. The information in RiMUP may be updated several times within its shelf life whenever there is an update in the package insert. There could be differences between the version of RiMUP shown here and other information in the public domain depending on the country regulatory’s requirement.
  4. NPRA has used its best endeavours in publishing this information but the information in RiMUP may not be the most up-to-date version for this product.
  5. If a RiMUP for your medicine is not available yet, please consult your doctor or pharmacist for advice.
  6. NPRA is unable to offer medical advice and that if a patient has any questions about a medicine they are taking they should contact their doctor or pharmacist. Patients should not stop taking any prescribed medicines without first consulting to a healthcare professional.
  7. Suspected adverse reactions to a medicine can be reported to NPRA by filling up the Reporting Form for Medicines Complaints by Consumers in this website [Consumers →Reporting Side Effects to Medicines (ConSERF) or Vaccines (AEFI)].
  8. NPRA does not accept liability for any injury, loss or damage incurred by use or reliance on the information provided in RiMUP.

RiMUP is available for prescription and non-prescription medicines registered for use in Malaysia. These leaflets are targeted for the consumer which are available in English and Malay version. You may download the leaflet and print it out for future reference. 

Under the circumstances where an approved RiMUP is unable to be found, kindly proceed to product search to view the document.

Other sources of medicine information:

www.knowyourmedicine.gov.my (Disease & Medicines) 
www.myhealth.gov.my (Ubat & Anda)

RiMUP (1912)

Zynor tablet

  • Active Ingredient/s: amlodipine
  • Company: Xepa-Soul Pattinson
  • Last Updated: 17-Aug, 2012
English version: Download

Zyprexa Tablet/ Zyprexa Zydis Orodispersible Tablet

  • Active Ingredient/s: Olanzapine
  • Last Updated: 1-Nov, 2017
Malay Version: Download English version: Download
<<  121 122 123 124 125 [126

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Newsletter Subsription

Site Last Modified

  • Last Modified: Friday 22 March 2019, 15:10:03.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Main Menu English

Choose Your Language